BioNTech

BioNTech’s Double Play: Cancer Vaccine Milestone and a New Legal Front Against Moderna

angelina -

BioNTech’s Defining Fortnight: Insider Sales, Founder Exodus, and a Pipeline Under the Microscope

angelina -

BioNTech’s €17 Billion War Chest Faces a Defining May as Insider Sale Precedes Earnings

Brett Shapiro -

BioNTech’s Cancer Bet Gathers Pace as Pipeline Data and Leadership Shifts Loom

Brett Shapiro -

BioNTech’s Shareholder Vote to Cement Strategic Overhaul

kashif hafeez -

BioNTech’s Cash Cushion Fuels High-Stakes Oncology Race

angelina -

BioNTech Charts Aggressive Oncology Path, Backed by Strong Cash Reserves

Brett Shapiro -

BioNTech’s Billion-Euro Oncology Bet Nears Key Regulatory Juncture

angelina -

BioNTech Faces Mounting Challenges as Key Trials and Leadership Changes Weigh on Sentiment

BioNTech战略转型：千亿储备护航，管理层寻求更大资本运作空间

kashif hafeez -

BioNTech’s Clinical Trial Halt Casts Shadow Over Future Revenue Streams

angelina -

BioNTech战略转型：后疫情时代的破局之路

kashif hafeez -

百欧恩泰的战略转型：千亿储备押注肿瘤治疗新时代

BioNTech’s Strategic Pivot Amid Regulatory and Revenue Challenges

Brett Shapiro -

BioNTech疫苗审批遇阻，肿瘤管线成转型关键

angelina -
123...8Page 1 of 8